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The chronic ethanol intake influence on the gluthatione S-transferase
(GST-P) and transforming growth factor α (TGF-α) expression in
remodeling/persistent preneoplastic lesions (PNLs) was evaluated in
the resistant hepatocyte model. Male Wistar rats were allocated
into five groups: G1, non-treated, fed water and chow ad libitum;
G2, non-treated and pair-fed chow (restricted to match that of G3
group) and a maltodextrin (MD) solution in tap water (matched
ethanol-derived calories); G3, fed 5% ethanol in drinking water and
chow ad libitum; G4, diethylnitrosamine (DEN, 200 mg/kg, body
weight) plus 200 parts per million of 2-acetylaminofluorene (2-AAF)
for 3 weeks and pair-fed chow (restricted to match that of G5 group)
and an MD solution in tap water (matched ethanol-derived calories);
G5, DEN/2-AAF treatment, fed ethanol 5% and chow ad libitum. All
animals were subjected to 70% partial hepatectomy at week 3 and
sacrificed at weeks 12 or 22, respectively. Liver samples were collected
for histological analysis or immunohistochemical expression of GST-
P, TGF-α and proliferating cell nuclear antigen or zymography for
matrix metalloproteinases-2 and -9. At the end of ethanol treatment,
there was a significant increase in the percentage of liver area
occupied by persistent GST-P-positive PNLs, the number of TGF-α-
positive PNLs and the development of liver tumors in ethanol-fed
and DEN/2-AAF-treated groups (G5 versus G4, P < 0.001). In addition,
ethanol feeding led to a significant increase in cell proliferation
mainly in remodeling and persistent PNLs with immunoreactivity for
TGF-α at week 22 (P < 0.001). Gelatinase activities were not altered
by ethanol treatment. The results demonstrated that ethanol enhances
the selective growth of PNL with double expression of TGF-α and
GST-P markers. (Cancer Sci 2008; 99: 221–228)
E thanol consumption is a widespread habit, especially in thewestern world, with imperative familial and socioeconomic
effects. Various studies have shown that chronic ethanol abuse
increases the risk of developing cancer of the breast, liver,
pancreas, colon and the upper aerial-digestive tract.(1–4) Alcohol
is a known risk factor for the development of hepatocellular
carcinoma (HCC), mainly in patients infected with the hepatitis
C virus (HCV) who drink heavily.(1,3) However, a direct correlation
between alcohol consumption and the development of HCC in
humans remains inconclusive.
The hepatocyte represents the major site of ethanol metabolism
using three main pathways, including alcohol dehydrogenase
(ADH), inducible CYP2E1 and catalase enzymes, leading to the
generation of acetaldehyde and reactive oxygen and nitrogen
species.(5,6) These free radicals can bind rapidly to cell constitu-
ents, including DNA, lipids and proteins, raising mainly oxida-
tive DNA damage, lipid peroxidation, protein impairment and
depletion of many antioxidant systems, including reductions in
glutathione, vitamin E and phosphatidylcholine.(6,7) In addition,
acetaldehyde is highly toxic, mutagenic and carcinogenic(8,9) and
the induction of CYP2E1 has been demonstrated to enhance the
activation of many xenobiotics, among them diethylnitrosamine
(DEN), a known carcinogen, genotoxic to the liver, present in many
alcoholic beverages, tobacco smoke, and dieting compounds.(10)
Recently, some studies have demonstrated that ethanol and its
metabolites, including acetaldehyde, can induce the production
of matrix metalloproteinases (MMPs) or inhibit the tissue inhibitors
of metalloproteinases (TIMPs) in the liver.(11–13) Ethanol and
acetaldehyde directly stimulate the production of transforming
growth factor beta-1 (TGFβ-1) and several extracellular matrix
(ECM) constituents and also alter TIMPs/MMPs regulation by
direct activation of hepatic stellate cells (HSCs), inducing liver
fibrosis.(11,12) In fact, acetaldehyde is a fibrogenic agent to the liver
inducing the expression of type-1 and type-3 collagen genes in
HSCs.(12) Also, in fibrotic liver there is an increased expression
of TIMPs, which play an important role in the regulation of
MMPs activities, including the gelatinases 2 and 9.(11–13)
There are some controversies in rodent liver carcinogenesis
assay concerning whether ethanol is a promoting agent(14–16) or
exerts cocarcinogenic effects(17,18) or neither.(19–21) The exact
mechanism(s) of ethanol-associated carcinogenesis remains obscure,
since this abuse drug per se is not considered a carcinogen in
experimental hepatocarcinogenesis studies.(1,22) The disagree-
ments between these data are probably due to differences in
experimental design: like different initiators used; moment of
ethanol administration (before, during or after carcinogen exposure);
preneoplasia and/or neoplasia end-points, and the rodent strain.(1)
The resistant hepatocyte (RH) model is a classic for the study
of the different steps of rat hepatocarcinogenesis. In this model,
DEN-initiating agent induces single cells and small foci of putative
initiated hepatocytes that are promoted with 2-acetylaminofluorene
(2-AAF) associated with a 70% partial hepatectomy (PH).(23) 2-AAF
is a mito-inhibitor to normal hepatocytes but does not inhibit a
subpopulation of glutathione S-transferase (GST-P)-positive hepato-
cytes. Partial hepatectomy acts as a mitotic stimulus resulting in
rapid growth of this subpopulation of initiated cells into larger
GST-positive lesions, while the surrounding liver parenchyma
remains quiescent. Some lesions eventually progress into grossly
visible nodules and, over months, tumors arise.(24,25)
Two phenomena occur following the promotional stimulus of
the RH protocol: remodeling (or phenotypic reversion) of lesions
and the proliferation and migration of oval cells. Hepatocytes
within remodeling lesions lose GST-P expression and other
enzymes common to preneoplastic liver lesions (PNL) and tend
to revert to a normal liver phenotype.(24–26) Remodeling occurs in
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most lesions following promotion and persistent PNL may
progress to HCC after several months.(24,25) The potential effect
of ethanol on the selective growth of putative preneoplastic
hepatocellular lesions is not well established. Therefore, the
present study was developed to investigate the differential
promoting effects of ethanol on remodeling and persistent PNL
expressing GST-P and transforming growth factor alpha (TGF-α)
phenotypes. In addition, the selective growth of PNL was
assessed by proliferating cell nuclear antigen (PCNA) and apop-
tosis rates. The activities of gelatinases (MMP-2 and MMP-9)
were investigated by zymography.
Materials and Methods
Animals and treatments. Four-week-old male Wistar rats were
obtained from the Multidisciplinary Center for Biological
Investigation (CEMIB, UNICAMP Campinas, SP, Brazil) and
housed in polypropylene cages (five animals/cage) covered with
metallic grids in a room maintained at 22 ± 2°C, 55 ± 10% humidity
and with a 12-h light-dark cycle. They were fed commercial Purina
chow (LABINA, Paul’nia, SP, Brazil) and water ad libitum for
a 2-week acclimation period. Then, the animals were randomly
divided into five experimental groups (Fig. 1). G1: non-treated,
fed water and chow ad libitum; G2: non-treated and pair-fed chow
(restricted to match that of the G3 group) and a maltodextrin
(MD, Neo-Nutri, Poços de Caldas, MG, Brazil) solution in tap
water (matched ethanol-derived calories); G3: fed 5% ethanol
(v/v) (Dinâmica Qu’mica, São Paulo, SP, Brazil) in tap water
and chow ad libitum; G4: diethylnitrosamine (DEN, Sigma-Aldrich,
St. Louis MO, USA) (200 mg/kg body weight) plus 200 parts
per million of 2-acetylaminofluorene (2AAF, Sigma-Aldrich) for
3 weeks(23) and pair-fed chow (restricted to match that of the G5
group) and an MD solution in tap water (matched ethanol-derived
calories); G5: DEN/2-AAF treatments plus 5% ethanol in tap
water and chow ad libitum. All animals were subjected to 70%
partial hepatectomy at week 3 and killed at either week 12 or 22
(5 and 15 weeks after the beginning of ethanol administration,
respectively). Food and liquid intakes were measured daily to
calculate the volume of solid food and of isocaloric MD solution
offered to the pair-fed groups. Body weight was measured twice a
week throughout the experiment. The protocols used were consistent
with the Ethical Principles for Animal Research adopted by the
Brazilian College of Animal Experimentation (COBEA).
Tissue processing, histology and immunohistochemical procedures.
At necropsy, the liver was removed, weighed, and fixed in 10%
phosphate-buffered formalin for 24 h. After fixation, representative
samples of liver were processed for paraffin embedding. The
paraffin blocks were cut into 5-µm-thick sections and stained
with hematoxylin-eosin (HE) for histological analysis, apoptosis
rates and for immunohistochemical analysis of GST-P, PCNA or
TGF-α antigens in serially sectioned liver slides.
Hepatic preneoplastic lesions (PNL, Fig. 1d) were classified
as altered foci of hepatocytes (AFH) or as hyperplastic nodules
(HN) with clear/eosinophilic, amphophilic, basophilic, tigroid
cell foci and mixed cell types, according to previously published
criteria.(27) AFH were considered PNL smaller than one hepatic
lobule, whereas HN comprised spherical PNL greater than or
equal to one hepatic lobule, without visible compression of the
surrounding liver. Liver tumors were classified as hepatocellular
adenoma (HA) or hepatocellular carcinoma (HCC), according to
the previously published criteria.(27)
Proliferating cell nuclear antigen, GST-P and TGF-α expression
were immunohistochemically detected as previously described.(28)
Briefly, deparaffinized 5-µm-thick serial liver sections on poly
L-lysine coated slides were treated with 3% H2O2 in phosphate-
buffered saline for 15 min, non-fat milk for 60 min, anti-PCNA
(clone PC10, 1:200 dilution), anti-GST-P (Medical and Biological
Laboratories, Tokyo, Japan, clone 311, 1:1000 dilution) clone
or anti-TGF-α (Oncogene Science Inc., New York, NY, USA,
clone Ab-2, 1:200 dilution) antibodies, biotinylated horse
antimouse IgG or antigoat IgG antibodies (Dako Corporation,
Carpinterie, CA, USA, 1:200 dilution) for 60 min, and streptavidin-
biotin-peroxidase solution (TissuGnost ABC Kit, Merck, Darmstadt,
Germany, 1:1:50 dilution). A pretreatment with 0.25% trypsin
(Sigma-Aldrich) for 15 min and 0.05% saponin (Calbiochem, La
Jolla, CA, USA) solution for 30 min was carried out for sections
submitted to TGF-α immunostaining.(28) Chromogen color develop-
ment was accomplished with 3,3′-diaminobenzidine tetrahydro-
chroride (DAB, Sigma-Aldrich) as the substrate to demonstrate
the sites of peroxidase binding. The slides were counterstained
with Harris’s hematoxylin (GST-P and TGF-α analysis) or with
HE (PCNA analysis).
Analysis of PNL expressing GST-P and TGF-a phenotypes. Preneo-
plastic lesions expressing uniform (distinct borders) and non-
uniform (indistinct borders) staining for GST-P were classified
as the persistent (Fig. 2a) and remodeling (Fig. 2b) phenotypes,
respectively.(29) GST-P-positive PNLs larger than 0.03 mm2 (~0.20 mm
in diameter) were measured using a Nikon photomicroscope
(Microphot-FXA, Tokyo, Japan) connected to a KS-300 apparatus
(Kontron Elektronic, Munich, Germany). Data were expressed
as number (PNL/cm2), mean size (mm2) and area (mm2/cm2) of
persistent and remodeling or total (persistent + remodeling) GST-P-
positive PNLs.
The number of clearly discernible TGF-α-positive PNLs (Fig. 2c)
per unit area of liver (cm2) was analyzed with the aid of a KS-300
system, as indicated above. The differential expression of TGF-α
in persistent and remodeling PNL was analyzed. The TGF-α-
positive PNLs were expressed as a percentage of persistent and
remodeling or total (persistent + remodeling) GST-P-positive PNLs.
Cell proliferation and apoptosis analysis. Liver PCNA labeling
(PCNA LI%) and apoptosis (AI%) indices for each animal from
groups G1 to G3 were calculated by counting the number of
immunohistochemically-labeled hepatocyte nuclei (S-Phase) per
total number of counted hepatocytes (∼1000) × 100. The PCNA
LI% and AI% indices within persistent or remodeling PNL,
expressing or not TGF-α phenotype, and in the surrounding
(non-focal) liver were determined (∼200–500 hepatocytes per
PNL and ∼2000 hepatocytes in non-focal liver, respectively).
Criteria for identification and quantification of hepatocytes in
apoptosis were taken from the published reports.(30)
Gelatin zymography for MMP-2 and MMP-9. Frozen samples of
liver (∼200 mg) were mechanically homogenized in 50 mM Tris
buffer pH 7.5 plus 0.25% triton-X 100 with a Polytron for 30 s
at 4°C, then centrifuged, and protein extracted on supernatant
was quantified by the Bradford method.(31) Aliquots (30 µg protein)
from liver extracts (nonaltered or with PNL) were subjected to
Fig. 1. Experimental protocol. b.w., body weight; n, number of rats;
S, sacrifice.
Pires et al. Cancer Sci | February 2008 | vol. 99 | no. 2 | 223
© 2008 Japanese Cancer Association
electrophoresis in gelatin containing polyacrylamide (8% acrylamide)
gels in the presence of sodium dodecyl sulfate under non-reducing
conditions. The gelatin substrate was present at 0.1% final
concentration in the gel. The gels (0.75-mm thick) were
electrophoresed for 2 h at 100 V, 4°C, in a Bio-Rad MiniProtean
II system (Bio-Rad Laboratories, Richmond, CA, USA). Following
electrophoresis, the gels were washed by gentle shaking at room
temperature with 2.5% Triton X-100 (two changes) for 1 h. The
gels were incubated overnight (18–20 h) in 50 mM Tris-HCl
(pH 8.4) containing 5 mM CaCl2 and 1 µM ZnCl2 at 37°C.
Following incubation, the gels were stained by Coomassie Blue.
Areas of proteolysis appeared as clear zones against a blue
background. Molecular mass determinations were made with
reference to prestained protein standards (Bio-Rad Laboratories)
co-electrophoresed into the gels. Image gels were captured and
the corresponding bands for each enzyme form were quantified
by densitometry as Integrated Optical Density (IOD) in an Image
Master VDS version 3.0 (Pharmacia Biotechnology, Piscataway,
NJ, USA). The values were analyzed statistically and plotted in
histograms.
Statistical analysis. Statistical analysis was made using the Jandel
Sigma Stat Software (Jandel Corporation, San Rafael, CA, USA).
Body weight, body-weight gain, absolute and relative liver weights,
PCNA-labeling and apoptosis indices and lesion multiplicity
were analyzed by Student’s t-test or Mann–Whitney test. The
incidence of different types of PNL and neoplastic lesions was
examined using χ2 or the Fischer exact tests. Data were
considered statistically significant when P < 0.05.
Results
General findings and biochemical analysis of ALT and AST. A total
of eight rats from DEN/2AAF-treated groups, six rats in DEN/
2-AAF-treated group (G4) and two rats in ethanol-fed and DEN/
2-AAF-treated group (G5), died during treatment with 2-AAF.
After 70% partial hepatectomy, some severe clinical signs of
toxicity such as reduced food intake and body-weight gain and
rough hair coat were observed in the majority of 2-AAF-treated
animals. A complete necropsy was not carried out in four rats
due to advanced postmortem changes. The presumed cause of
death was severe hepato-toxicity induced by 2-AAF.(32)
At the end of weeks 12 and 22, no differences in the final
body weight and body-weight gain were observed between the
experimental groups. The absolute and relative liver weights
from the DEN/2-AAF-treated groups (G4 and G5) were slightly
higher than the non-initiated/promoted groups (G1 to G3) but
not significantly (data not shown). The average daily intake of
ethanol was ~2.23–2.70 g/kg per day and did not differ between
the ethanol-treated groups (G3 and G5). Values for alanine
aminotransferase and aspartate aminotransferase were higher in
the ethanol fed and DEN/2-AAF-treated group (G5) than in the
other groups but without significance at the end of week 22
(data not shown).
Histological findings. Liver histological analysis did not show
PNL or neoplastic lesions in the non-initiated/promoted groups
(G1 to G3) at weeks 12 and 22 (data not shown). Similarly,
lesions indicative of hepatic injury such as steatosis, fibrosis and
inflammation were not observed in ethanol-fed animals (G3)
(data not shown).
Table 1 summarizes data for the incidence of PNL and liver
tumors such as hepatocellular adenomas and carcinomas in
DEN/2-AAF-treated groups (G4 and G5). Treatment with 5%
ethanol did not alter the incidence of the different types of PNL
or neoplastic lesions at the end of weeks 12 and 22. In contrast,
the mean number/group and multiplicity of liver tumors were
significantly higher in the ethanol-fed and DEN/2-AAF-treated
group (G5) when compared with the DEN/2-AAF-treated group
(G4) at week 22 (P = 0.001, P = 0.002, respectively) (Table 1).
Analysis of GST-P and TGF-α-positive PNL. Data from GST-P analysis
of the groups submitted to the resistant hepatocyte protocol is
summarized in Table 2. The non-initiated/promoted groups (G1
to G3) did not develop any GST-P-positive PNLs above the
established cut off value (0.20 mm in diameter) at the end of 12
and 22 weeks (data not shown). In week 12, the number and
Fig. 2. (a) Remodeling (R) and persistent (P)
gluthatione S-transferase (GST-P)-positive preneo-
plastic lesions (PNLs) (20× objective); (b–e) Serial
liver section showing a persistent PNL with
immunoexpression for GST-P (b) or transforming
growth factor-α (TGF-α) (c) and hematoxylin-eosin
(HE) stained (d). PCNA, proliferating cell nuclear
antigen. Bar, 100 µm.
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percentage of liver area occupied by total (persistent + remodeling),
persistent or remodeling GST-P-positive PNLs were not influenced
by treatment with 5% ethanol. The number of remodeling PNLs
was higher than the persistent PNLs but the mean size of
persistent PNLs was approximately 1.6–2.0 times larger than
those of remodeling PNLs, resulting in similar values of the
percentage liver area occupied by these PNLs for both G4 and
G5 groups. However at week 22, the number of remodeling
PNLs per unit area of liver was significantly lower in the
ethanol-fed and DEN/2-AAF-treated group (G5) when compared
with the DEN/2-AAF-treated group (G4) (P < 0.001). The mean
size and percentage of liver area occupied by total (persistent +
remodeling) and persistent GST-P-positive PNLs were significantly
higher in the ethanol-fed and DEN/2-AAF-treated group (G5)
when compared with the DEN/2-AAF-treated group (G4)
(P = 0.002, P < 0.002 and P < 0.001, respectively). The mean
size of persistent PNLs was approximately 2.7 times larger than
remodeling PNLs, resulting in significantly higher values of
percentage liver area occupied by this latter PNL when compared
with the G4 group. Also, in this group persistent PNLs were
approximately 1.5 larger than those of remodeling PNLs.
Table 3 summarizes data from double-positive foci for TGF-α
and GST-P markers in the groups submitted to the resistant
hepatocyte protocol. The immunohistochemical study of hepatocellular
Table 1. Incidences of liver preneoplastic lesions (PNLs) and neoplastic lesions in DEN/2-AAF treated groups
Treatment (Group)
Types of PNL§ Neoplastic lesions
CCF ECF BCF HA HCC Number/group Multiplicity†
12 weeks
DEN + 2-AAF + MD (G4, n = 7)‡ 6 (86%) 7 (100%) 6 (86%) 5 (71%) 0 1.56 ± 2.24 2.29 ± 2.21 (22)‡
DEN + 2-AAF + 5% EtOH (G5, n = 8) 6 (75%) 8 (100%) 5 (63%) 6 (75%) 0 3.14 ± 3.28 4.40 ± 2.73 (16)
22 weeks
DEN + 2-AAF + MD (G4, n = 15) 7 (46%) 15 (100%) 15 (100%) 13 (87%) 0 1.87 ± 1.13 2.15 ± 0.90 (29)
DEN + 2-AAF + 5% EtOH (G5, n = 18) 8 (44%) 18 (100%) 18 (100%) 17 (94%) 1 (6%) 5.00 ± 3.24* 5.29 ± 3.08 (90)§
P-value = 0.001 = 0.002
2-AAF, 200 parts per million of 2-acethylaminofluorene; 5% EtOH, 5% ethanol (v/v); BCF, basophilic cell PNL; CCF, clear cell PNL; DEN, 200 mg/kg 
of diethylnitrosamine; ECF, eosinophilic cell PNL; HA, hepatocellular adenoma; HCC, hepatocellular carcinoma; MD, maltodextrin solution; 
n, effective number of animals. †Number of tumors/tumor-bearing rats; ‡Total number of tumors/group; §Significantly different from G4 group.
Table 2. Analysis of gluthatione S-transferase (GST-P)-positive preneoplastic lesions (PNLs) with remodeling and/or persistent phenotypes in
DEN/2-AAF-treated groups†
Treatment (Group)
Number of GST-P-positive PNLs 
per unit area of liver (cm2) Mean size of GST-P-positive PNLs (mm2) Area occupied by GST-P-positive PNLs (%)
Total‡ P R Total P R Total P R
12 weeks
DEN + 2-AAF + MD (G4) 73.69 ± 15.48 26.40 ± 4.07 47.29 ± 13.23 0.62 ± 0.41 0.92 ± 0.48 0.57 ± 0.26 45.01 ± 26.01 22.12 ± 14.91 22.89 ± 12.64
DEN + 2-AAF + 5% EtOH (G5) 60.15 ± 5.74 22.06 ± 5.58 38.09 ± 2.14 0.79 ± 0.39 1.17 ± 0.16 0.57 ± 0.08 48.20 ± 8.04 26.47 ± 10.34 21.72 ± 3.11
22 weeks
DEN + 2-AAF + MD (G4) 66.59 ± 14.67 25.55 ± 7.72 41.04 ± 8.77 0.72 ± 0.59 0.92 ± 0.38 0.62 ± 0.34 47.04 ± 14.35 21.45 ± 5.27 25.58 ± 9.94
DEN + 2-AAF + 5% EtOH (G5) 55.42 ± 18.91 28.52 ± 5.30 26.89 ± 5.31§ 1.1 ± 0.81* 1.53 ± 0.39§ 0.57 ± 0.36 62.59 ± 16.57§ 41.11 ± 11.44§ 21.49 ± 9.46
P-value < 0.001 = 0.002 < 0.002 = 0.010 < 0.001
†Values are means ± standard deviation. §Significantly different from the G4 group. ‡Total = persistent + remodeling PNL. 2-AAF, 200 parts per million of 
2-acethylaminofluorene; 5% EtOH, 5% ethanol (v/v); DEN, 200 mg/kg of diethylnitrosamine; MD, maltodextrin solution; P, persistent PNL; R, remodeling PNL. 
Table 3. Analysis of development of preneoplastic lesions (PNLs) with double expression for transforming growth factor-α (TGF-α)/gluthatione
S-transferase (GST-P) in DEN/2-AAF treated groups†
Treatment (Group)
Number of TGF-α-positive PNL per unit area 
of liver (cm2)
Relation between GST-P and TGF-α-positive 
staining (%)§
Total‡ P R GST-P + /TGF-α+§ P¶ R¶
12 weeks
DEN + 2-AAF + MD (G4) 5.21 ± 2.26 4.94 ± 2.09 0.27 ± 0.32 9.21 ± 5.23 95.59 ± 5.34 4.41 ± 5.34
DEN + 2-AAF + 5% EtOH (G5) 4.69 ± 3.75 4.41 ± 3.53 0.27 ± 0.26 10.97 ± 8.71 94.16 ± 4.44 5.84 ± 4.44
22 weeks
DEN + 2-AAF + MD (G4) 3.91 ± 1.41 3.66 ± 1.29 0.25 ± 0.21 9.23 ± 4.80 94.31 ± 4.82 5.69 ± 4.82
DEN +2-AAF + 5% EtOH (G5) 10.77 ± 6.78†† 10.12 ± 5.91†† 0.65 ± 0.90‡‡ 19.97 ± 10.23†† 94.86 ± 3.77 5.14 ± 3.77
P-value < 0.001 < 0.001 = 0.095 = 0.008
†Values are means ± SD. ‡Total = persistent + remodeling PNL.§Percentage positive for both GST-P and TGF-α immunostaining. ¶Percentage of 
remodeling or persistent PNL positive for TGF-α. ††Significantly different from the G4 group. ‡‡Trend toward difference from the G4 group. 
2-AAF, 200 parts per million of 2-acethylaminofluorene; 5% EtOH, 5% ethanol (v/v); DEN, 200 mg/kg of diethylnitrosamine; MD, maltodextrin 
solution; P, persistent PNL; R, remodeling PNL. 
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lesions revealed that the immunoreactivity for TGF-α was
homogenous and intense in HA and HCC and often heterogene-
ous in most PNLs and was more frequently observed in persist-
ent rather than in remodeling GST-P-positive PNLs (Fig. 1b,c)
in both DEN/2-AAF-treated groups (G4 and G5). At week 22, a
significant increase in the number of PNLs (per unit area of liver
[cm2]) with expression of TGF-α, and in the percentage of PNL
with double expression for TGF-α/GST-P were observed in the
ethanol-fed and DEN/2-AAF-treated group (G5) when com-
pared with the DEN/2-AAF-treated group (G4) (P < 0.001 and
P < 0.008, respectively). Besides the clear promoting effects of
ethanol feeding on total (persistent and remodeling) and in per-
sistent GST-P/TGF-α phenotypes, a trend toward an increase in
the number of remodeling PNL/TGF-α-positive was also observed
in the ethanol-fed and DEN/2-AAF-treated group (G5) although
not at a statistically significant level.
PCNA labeling and apoptosis analysis in PNL. The effects of ethanol
on cell proliferation and apoptosis rates in remodeling and
persistent PNLs are shown in Figs 3 and 4, respectively. In
general, PCNA LI% and AI% indices were high in persistent
PNLs and a very low percentage of apoptosis was observed in
remodeling and surrounding liver. In week 12, ethanol feeding
(G5) did not change the PCNA LI% within either the persistent
and remodeling PNLs or in the surrounding non-focal liver
when compared with the DEN/2-AAF-treated group (G4) (data
not shown). On the other hand, at week 22, a significant
increase in PCNA LI% was observed mainly in persistent and
remodeling PNLs expressing TGF-α phenotype in the ethanol-fed
and DEN/2-AAF-treated group (G5) when compared with the
DEN/2-AAF-treated group (G4) (P = 0.010 and P = 0.009,
respectively). Ethanol at 5% did not change the apoptosis rates
within the remodeling and persistent PNLs in both TGF-α-positive
and TGF-α-negative PNLs at week 12 (data not shown). A slight
not significant increase in AI% was observed in remodeling
PNLs expressing TGF-α phenotype in the ethanol-fed and DEN/2-
AAF-treated group (G5) at week 22.
In the non-initiated/promoted groups (G1 to G3), neither ethanol
nor maltodextrin intake changed cell proliferation or apoptosis
rates in the liver (data not shown).
MMP-2 and -9 activities. The activity of MMP-2 and -9 was
measured by gelatin zymography at weeks 12 (not shown) and
22 (Fig. 5a). The zymography of all experimental groups showed
clear bands of gelatinolytic activity with 92, 72, 64 and 59 kDa,
which corresponded to active-MMP-9, pro-MMP-2, intermediate-
MMP-2 and active-MMP-2, respectively. Analysis of the integrated
optic density (IOD) of the bands revealed that liver gelatinase
activities were not significantly altered either by ethanol treatment
or by exposure to the chemical carcinogens (DEN/2-AAF) in
Fig. 3. Effects of ethanol at 5% on proliferating cell nuclear antigen
(PCNA) LI% in total, persistent and remodeling preneoplastic lesions
(PNLs) expressing or not expressing transforming growth factor-α (TGF-α)
and in the surrounding liver at 22 week. Total (persistent plus
remodeling PNL). P, remodeling PNL; R, remodeling PNL. *Significantly
different from the G4 group.
Fig. 4. Effects of ethanol at 5% on the apoptosis indices (AI%) in
total, persistent and remodeling preneoplastic lesions (PNLs) expressing
or not expressing transforming growth factor-α (TGF-α) and in the
surrounding liver at 22 week. Total (persistent plus remodeling PNL).
P, remodeling PNL; R, remodeling PNL. §Trend toward difference from
the G4 group.
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both non-initiated/promoted and DEN/2-AAF-treated groups
(Fig. 5b).
Discussion
The present study showed that chronic 5% ethanol administration
promotes chemically-induced rat hepatocarcinogenesis in the
resistant hepatocyte model. The tumor-promoting potential of
ethanol involved mainly the expansion of double GST-P/TGF-
α-positive PNL with enhancement of cell proliferation, without
alterations in the apoptosis rates or gelatinase activities. Also,
ethanol increased tumor burden by enhancing the number and
multiplicity of neoplastic lesions in the liver of the DEN/2-
AAF-treated animals. Kushida et al. (2005) have determined a
threshold level for the promoting effect of ethanol on rat
hepatocarcinogenesis.(16) These authors observed that ethanol in
concentrations lower than 3% has a weak or even nonexistent
effect on the promotion of preneoplastic GST-P-positive liver foci.
In the present study, a 5% ethanol concentration was used, and our
findings are in agreement with the previously proposed threshold
for ethanol on the promotion of rat hepatocarcinogenesis.(16)
The remodeling, or phenotypic reversion is a process where
the initiated hepatocyte gradually loses the expression of some
preneoplastic markers, such as GST-P and γ-GGT, and returns to
a normal phenotype.(24–26,33) This process occurs naturally in the
early stages of the multistep process of chemically induced
hepatocarcinogenesis and is under genetic control.(34) GST-P is a
suitable marker for putative preneoplastic foci of altered hepatocytes
and hepatic nodules (PNLs) in chemically-induced rat hepato-
carcinogenesis.(24–26) A typical feature of PNLs is their capability
of expressing one of two options: spontaneously remodeling to
a normal appearing liver by the majority (95–98%) or persist-
ence with cell proliferation and evolution to cancer by a small
minority (2–5%).(25,26) Persistence of PNLs could indicate a block
in remodeling by loss of differentiation or apoptosis and appears
to be linked to enhanced evolution of hepatocellular carcinoma.(25,26)
The present study demonstrated that chronic intake of 5% ethanol
increased the mean size and the percentage of liver area occu-
pied by total (persistent and remodeling) and persistent GST-P-
positive PNLs, with reduction in the number of remodeling
GST-P-positive PNLs. Taken together, these data show that eth-
anol has a selective effect on the expansion of persistent PNLs.
This is similar to the other tumor promoters of hepatocarcino-
genesis like phenobarbital and nafenopin,(30) which act by inhibiting
or delaying the normal remodeling process and by enhancing
cell growth and size of the persistent lesions, which are thought
to be precursors of HCC.
Various alterations in the expression of proto-oncogenes occur
during the process of hepatocarcinogenesis, including an increase
in the expression of TGF-α.(35–38) This growth factor activates the
tyrosine kinase activity of the epidermal growth factor receptor,
and its overexpression has been linked to tumorigenesis in trans-
genic mice, which were found to present a high incidence of
spontaneous malignant liver tumors.(39,40) Immunohistochemical
expression of TGF-α has been demonstrated in rodent hepatic
preneoplastic and neoplastic lesions(35–38) although a few GST-P-
positive PNLs (∼10%) exhibit immunoreactivity for TGF-α.(38)
It has been shown that PNLs with double positivity for GST-P
and TGF-α show higher levels of cell proliferation than TGF-α-
negative PNLs and this could represent a potential lesion for
progression to liver tumors.(37,38) The selective increase of TGF-
α-positive PNLs induced by ethanol could indicate a promoting
effect, since this growth factor may act as a potent hepatocyte
mitogen in the progression of liver carcinogenesis.(37,38) Also,
high concentrations of TGF-α were found in an in vitro assay
using HepG2 cells exposed to ethanol, suggesting that this growth
factor may play an important role in the liver response to this
abuse drug.(41) In the present study we have found that chronic
ethanol intake enhanced the number of TGF-α-positive PNLs
per unit area of liver, and this enhancement mainly occurred in
the persistent PNLs, suggesting that these lesions may have a
growth advantage over the remodeling PNLs. Interestingly,
almost 95% of the total TGF-α-positive PNLs exhibited a per-
sistent phenotype, which corroborates the hypothesis that this
growth factor may be a key peptide for tumor progression in
experimental hepatocarcinogenesis.(34,37,38)
The increase in cell proliferation and apoptosis rates in prene-
oplastic and neoplastic lesions during the multisteps of liver car-
cinogenesis have been described.(42,43,45) One of the mechanisms
proposed for the promoting effect of ethanol on rat hepatocar-
cinogenesis is by enhancement of cell proliferation observed
during or after interruption of long-term alcohol exposure.(14,15,44)
In the present study, the mean rates of cell proliferation were
significantly higher in TGF-α-positive than in TGF-α-negative
PNLs. Ethanol feeding at 5% resulted in clear promoting activ-
ity as observed by the increased percentage of the liver occupied
by PNLs and mean PNL size. The cell proliferation increase in
the remodeling PNLs with immunoexpression for TGF-α could
be related to a trend toward the persistent phenotype, thus
reducing the number of this type of hepatocellular lesion.
Ethanol feeding did not change the apoptosis rates within
persistent or remodeling PNLs in both TGF-α-positive and
-negative phenotypes at 12 and 22 weeks. Thus, apoptosis may
not play an important role in the promoting effects of ethanol in
the preneoplasia stage of rat hepatocarcinogenesis. In fact,
previous studies have shown that PNL growth during the initial
stages of rat hepatocarcinogenesis is not consistent with the
concept of apoptosis failure.(42,43,45)
Matrix metalloproteinases are a family of proteases involved
in many physiological and pathological processes(45) such as
angiogenesis, tumor invasion and metastasis. MMP-2 and -9 are
produced in the liver by activated HSCs(12,13) in response to
extracellular matrix changes induced by many agents, including
ethanol.(13) Ethanol itself is a stimulating agent for the release of
activated gelatinases in cultured fibroblasts and breast cancer
Fig. 5. Gelatin zymography analysis of matrix metalloproteinase-2
(MMP-2) and MMP-9 activities in the liver at week 22. (a) Clear bands
with 92, 72, 64 and 59 kDa correspond to pro-MMP-9, pro-MMP-2,
intermediate-MMP-2 and active-MMP2, respectively. (b) Densitometric
analysis of gelatinolytic bands. Data are expressed as means ± standard
deviation (SD).
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cells.(47,48) In the present study, ethanol feeding did not change
the activity of these proteases in either the non-initiated/pro-
moted or DEN/2-AAF groups. This is in agreement with the his-
tological findings of the absence of liver inflammation, necrosis
and fibrosis in the groups exposed to ethanol.
Some studies demonstrated that ethanol exerts a promoting
activity on rat hepatocarcinogenesis.(14–16) However, few investi-
gations have examined this effect at low ethanol doses and little
attention has been given to the differential effects of ethanol on
PNL phenotypic diversities. The results of the present study
show that chronic feeding of ethanol at a low dose promotes a
selective growth of remodeling and persistent PNLs with double
GST-P/TGF-α markers. Thus, the expression of TGF-α may be
a pathway for the promoting activity of ethanol toward rat hepa-
tocarcinogenesis. Further studies on the role of ethanol in the
mechanisms of hepatocarcinogenesis should continue to be
carried out.
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